Akt activity in Alzheimer's disease and other neurodegenerative disorders

Enzyme activities of the serine/threonine kinase Akt were compared in mid-temporal and mid-frontal cortices from Alzheimer's disease cases and matched controls. Activities (GSK-3&agr;/&bgr; fusion protein phosphorylation by immunoprecipitated Akt) were significantly increased in temporal cortex soluble fractions from Alzheimer's disease compared with non-disease controls and positive disease controls with another neurodegenerative disease. Temporal cortex soluble fraction Akt activities positively correlated with Braak staging for neurofibrillary changes. Frontal cortex soluble fraction activities were significantly reduced in positive disease compared with Alzheimer's disease cases and non-disease controls. Strong Ser473 Akt immunoreactivity was seen in Alzheimer's disease pyramidal neurons likely undergoing degeneration and in reactive astroglia. Non-disease and positive disease controls showed moderate Ser473 Akt immunostaining of occasional pyramidal neurons.

[1]  F. Liu,et al.  FRAT1 peptide decreases Aβ production in swAPP751 cells , 2003 .

[2]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[3]  H. Braak,et al.  Role of protein kinase B in Alzheimer's neurofibrillary pathology , 2003, Acta Neuropathologica.

[4]  I. Ferrer,et al.  Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration , 2002, Acta Neuropathologica.

[5]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[6]  B. Hemmings,et al.  Ten years of protein kinase B signalling: a hard Akt to follow. , 2001, Trends in biochemical sciences.

[7]  S. Doré,et al.  Protective and Rescuing Abilities of IGF‐I and Some Putative Free Radical Scavengers against β‐Amyloid‐Inducing Toxicity in Neurons , 1999, Annals of the New York Academy of Sciences.

[8]  H. Braak,et al.  Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes , 1999 .

[9]  A. Windebank,et al.  Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. , 1998, Journal of neurobiology.

[10]  A. Takashima,et al.  Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons , 1998, Neuroscience Research.

[11]  E. Braak,et al.  Distribution, Levels, and Activity of Glycogen Synthase Kinase‐3 in the Alzheimer Disease Brain , 1997, Journal of neuropathology and experimental neurology.

[12]  Christina A. Wilson,et al.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.

[13]  Feng Liu,et al.  FRAT1 peptide decreases Abeta production in swAPP(751) cells. , 2003, FEBS Letters.

[14]  H. Braak,et al.  Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. , 1999, Journal of neuropathology and experimental neurology.

[15]  A. Takashima,et al.  Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. , 1998, Neuroscience research.